Attention deficit hyperactivity disorder and substance use disorders

Current Topics in Behavioral Neurosciences

Volumn 9, Issue , 2012, Pages 145-172

  Bukstein, Oscar G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ADHD; Adolescents; Drug abuse; Substance use disorders

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CLONIDINE; COCAINE; DEXAMPHETAMINE; DOPAMINE; GUANFACINE; IMIPRAMINE; METHAMPHETAMINE; MODAFINIL; NORTRIPTYLINE; PSYCHOSTIMULANT AGENT; VENLAFAXINE; CENTRAL STIMULANT AGENT;

ANTISOCIAL PERSONALITY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE THERAPY; COMORBIDITY; CONDUCT DISORDER; CONTINUOUS PERFORMANCE TEST; DELINQUENCY; DEPRESSION; DSM-IV; GENETIC ASSOCIATION; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SMOKING; SUBSTANCE ABUSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION DISORDERS; GENETICS; HUMAN; SUBSTANCE-RELATED DISORDERS;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 84887607512     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2011_148     Document Type: Article

References (146)

1. Advokat C (2007) Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord 11:8-16
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual, Fourth Edition Text Revision (DSM-IV TR). American Psychiatric Publishing, Arlington, VA
3. August GJ, Winters KC, Realmuto GM, Fahnhorst T, Botzet A, Lee S (2006) Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry 45:824-832
4. Balstey RL, Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 20:119-129
5. Barkley RA (2010) Attention-deficit/hyperactivity disorder, executive functioning, and self-regulation. In: Baumeister RF, Vohs KD (eds) Handbook of self-regulation: research, theory, and applications, 2nd edn. Guilford, New York, NY, pp 551-564
6. Barkley RA, Fischer M, Edelbrock CS, Smallish L (1990) The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557
7. Barkley R, Fischer M, Smallish L, Fletcher K (2002) The persistence of attention deficit hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111:279-289
8. Bekker EM, Bocker KB, Van Hunsel F, van den Berg MC, Kenemans JL (2005) Acute effects of nicotine on attention and response inhibition. Pharmacol Biochem Behav 82:539-548
9. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV (1995) Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652-1658
10. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S et al (1997) Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective followup study. J Am Acad Child Adolesc Psychiatry 36:21-29
11. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ et al (2005) Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116:e777-e784
12. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV (2008a) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 165:597-603
13. Biederman J, Petty CR, Wilens TE, Fraire MG, Purcell CA, Mick E et al (2008b) Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 165:107-115
14. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al (2006) Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63:808-816
15. Brookes K, Xu X, Chen W, Zhou K, Neale N, Lowe N et al (2006) The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 1:934-953
16. Carroll KM, Rounsaville BJ (1993) History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 34:75-82
17. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP et al (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53:607-616
18. Chait LD (1994) Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 5:281-288
19. Chan YF, Dennis ML, Funk RR (2008) Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. J Subst Abuse Treat 34:14-24
20. Charach A, Yeung E, Climans T, Lillie E (2011) Childhood attention deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 50:9-21
21. Coetzee M, Kaminer Y, Morales A (2002) Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Subst Abus 23:165-169
22. Congdon E, Lesch KP, Canli T (2007) Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet 147B:27-32
23. Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW et al (2003) Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 70:29-37
24. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP (2005) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30:205-211
25. Davidson JT, Connor KM (1998) Bupropion sustained release: a therapeutic overview. J Clin Psychiatry 58(suppl 4):25-31
26. Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, Javitch JA et al (2002) Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290:1545-1550
27. DiChiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278
28. Elkins IJ, McGue M, Iacono WG (2007) Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 64:1145-1152
29. Ercan ES, Coskunol H, Varan A, Toksoz K (2003) Childhood attention deficit/hyperactivity disorder and alcohol dependence: a 1-year follow-up. Alcohol 38:352-356
30. Everitt BJ, Belin D, Economidou D, Robbins TW (2008) Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Phil Trans R Soc Lond B Biol Sci 363:3125-3135
31. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313-1323
32. Faraone SV, Wilens TE, Petty C, Natshel K, Spencer T, Biederman J (2007a) Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict 16 (S1):24-34
33. Faraone SV, Biederman J, Wilens TE, Adamsen JJ (2007b) A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 37:1743-1752
34. Fayyad J, De Graaf R, Kessler R, Slonso J, Angermeyer M, Demyttenaere K et al (2007) Crossnational prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402-409
35. Fergusson DM, Horwood LJ, Ridder EM (2007) Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study. Drug Alcohol Depend 88(Suppl 1):S14-S26
36. Fillmore MT, Rush CR, Hays L (2006) Acute effects of cocaine in two models of inhibitory control: implications of non-linear dose effects. Addiction 101:1323-1332
37. Flory K, Milich R, Lynam DR, Leukefeld C, Clayton R (2003) Relation between childhood disruptive behavior disordersand substance use and dependence symptoms in young adulthood: individuals with symptoms of attention-deficit/hyperactivity disorder and conduct disorder are uniquely at risk. Psychol Addict Behav 17:151-158
38. Fredericks EM, Kollins SH (2004) Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology 175:391-398
39. Galanter M, Kleber HD (eds) (2008) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Arlington, VA
40. Galer C, Bouvard MP, Messiah A, Fombonne E (2008) Hyperactivity-inattention symptoms in childhood and substance use in adolescence: the youth gazel cohort. Drug Alcohol Depend 94:30-37
41. Garavan H, Stout JC (2005) Neurocognitive insights into substance abuse. Trends Cogn Sci 9:195-201
42. Garavan H, Kaufman JN, Hester R (2008) Acute effects of cocaine on the neurobiology of cognitive control. Phil Trans R Soc Lond B Biol Sci 363:3267-3276
43. Gehricke JG, Hong N, Wigal TL, Chan V, Doan A (2011) ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav 98:485-491
44. Goksoyr PK, Nottestad JA (2008) The burden of untreated ADHD among adults: the role of stimulant medication. Addict Behav 33:342-346
45. Goldstein RZ, Tomasi D, Alia-Klein N, Tomasi D, Zhang L, Cottone LA et al (2007) Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and selfcontrol in cocaine addiction? Am J Psychiatry 164:43-51
46. Goldstein RZ, Craig AD, Bechara A, Garavan H, Childress AR, Paulus MP et al (2009a) The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci 13:372-380
47. Goldstein RZ, Alia-Klein N, Tomasi D et al (2009b) Anterior cingulated cortex hypoactivations to an emotionally salient task in cocaine addiction. Proc NAtl Acad Sci U S A 106:9453
48. Gordon SM, Tulak F, Troncale J (2004) Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence. J Addict Dis 23:31-40
49. Griffith JD, Carranza J, Griffith C, Miller LI (1983) Bupropion: clinical essay for amphetaminelike potential. J Clin Psychiatry 44:206-208
50. Grüsser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M et al (2004) Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl) 175:296-302
51. Guan L, Wang B, Chen Y, Yang L, Li J, Qian Q et al (2009) A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry 14:546-554
52. Guindalini C, Howard M, Haddley K, Lanaranjeira R, Collier D, Ammar N et al (2006) A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A 103:4552-4557
53. Hamarman S, Fossella J, Ulger C (2004) Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 14:564-574
54. Hatsukami D, Fletcher L, Morgan S, Keenan R, Amble P (1989) The effects of varying cigarette deprivation duration on cognitive and performance tasks. J Subst Abuse 1:407-416
55. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF et al (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
56. Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH (1998) Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779:214-225
57. Hoza B, Gerdes AC, Hinshaw SP et al (2004) Self-perceptions of competence in children with ADHD and comparison children. J Consult Clin Psychol 72:382-391
58. Hurt RD, Sachs PL, Glover ED, Offord KP, Johnston JA, Dale LC et al (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202
59. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ (2005) Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 15:764-776
60. Ken L, Greene E, Holmes J, Thapar A, Gill M, Hawi Z et al (2001) No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder. Am J Med Genet 105:686-689
61. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716-723
62. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367-374
63. Kollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68:611-627
64. Kollins SH, McClernon FJ, Fuemmeler BF (2005) Association between smoking and attentiondeficit/ hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 62:1142-1147
65. Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK (2009) Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology 204:73-83
66. Koob GF, Nestler EJ (1997) The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 9:482-497
67. Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31:533-544
68. Lee J, Laurin N, Crosbie J, Ickowicz A, Pathare T, Malone M et al (2008) Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes Brain Behav 7:53-60
69. Lee SS, Humphreys KL, Flory K, Liu R, Glass K (2011) Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev 31:328-341
70. Levin FR, Evans SM, Brooks DJ, Kalbag AP, Garawi F, Nunes EV (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion, and placebo. Drug Alcohol Depend 81:137-148
71. Levin FR, Evans SM, Brooks DJ, Garawi F (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20-29
72. Li MD, Ma JZ, Beuten J (2004) Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 66:382-392
73. MacDonald FE, Kollins SH (2005) A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15:729-741
74. Maher BS, Marazita ML, Ferrell RE et al (2002) Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr Genet 12:207-215
75. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA (1991) Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 48:77-83
76. Mannuzza S, Klein RG, Truong NL, Moulton JL, Roizen ER, Howell KH et al (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165:604-609
77. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK (2004) Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12thgrade students in the United States, 2001. J Adolesc Health 35:501-504
78. McCabe SE, Teter CJ, Boyd CJ (2006) Medical use, illicit use, and diversion of prescription stimulant medication. J Psych Drugs 38:43-56
79. McClernon FJ, Kollins SH (2008) ADHD and smoking: from genes to brain to behavior. Ann NY Acad Sci 1141:131-147
80. McClernon FJ, Fuemmeler BF, Kollins SH, Kail ME, Ashley-Koch AE (2008a) Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. Nicotine Tob Res 10:117-127
81. McClernon FJ, Kollins SH, Lutz AM, Fitzgerald DP, Murray DW, Redman C et al (2008b) Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology 197:95-105
82. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE et al (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162:1621-1627
83. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
84. Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997a) ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:37-44
85. Milberger S, Biederman J, Faraone SV, Wilens T, Chu MP (1997b) Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 6:318-329
86. Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24:167-202
87. Molina BS, Pelham WE (2003) Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 112:497-507
88. Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM et al (2007a) Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46:1028-1040
89. Molina BS, Pelham WE, Gnagy EM (2007b) Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. Alcohol Clin Exp Res 31:643-654
90. Munafo M, Clark T, Johnstone E, Murphy M, Walton R (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6:583-597
91. Novak SP, Kroutil LA, Williams RL, Van Brunt DL (2007) The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2:32
92. Owens J, Goldfine M, Evangelista N, Hoza B, Kaiser NM (2007) A critical review of selfperceptions and the positive illusory bias in children with ADHD. Clin Child Fam Psychol Rev 10:335-351
93. Paulus MP, Tapert SF, Schuckit MA (2005) Neural activation patterns of methamphetaminedependent subjects during decision making predict relapse. Arch Gen Psychiatry 62:761-768
94. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS (1995) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7:373-378
95. Poulin C (2001) Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. Can Med Assoc J 165:1039-1044
96. Powell J, Dawkins L, Davis RE (2002) Smoking, reward responsiveness, and response inhibition: tests of an incentive motivational model. Biol Psychiatry 51:151-163
97. Rahman S, Zhang J, Engleman EA, Corrigall WA (2004) Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study. Neuroscience 129:415-424
98. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ (1980) Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943
99. Renthal W, Nestler EJ (2008) Epigenetic mechanisms in drug addiction. Trends Mol Med 14:341-350
100. Resnick RB, Kestenbaum RS, Schwartz LK (1977) Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 195:696-698
101. Riggs P (2009) Multi-site study of OROS-MPH for ADHD in substance-abusing adolescents. In: Scientific Proceedings of the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI, pp 94-95
102. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A (2004) A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry 43:420-429
103. Rinn W, Desai N, Rosenblatt H, Gastfriend DR (2002) Addiction denial and cognitive dysfunction: a preliminary investigation. J Neuropsychiatry Clin Neurosci 14:52-57
104. Roehrs T, Papineau K, Rosenthal L, Roth T (1999) Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharmacol 7:145-150
105. Rohde P, Kahler CW, Lewinsohn PM, Brown RA (2004) Psychiatric disorders, familial factors, and cigarette smoking: II. Associations with progression to daily smoking. Nicotine Tob Res 6:119-132
106. Rohsenow DJ, Monti PM, Rubonis AV, Sirota AD, Niaura RS, Colby SM et al (1994) Cue reactivity as a predictor of drinking among male alcoholics. J Consult Clin Psychol 62:620-626
107. Rugino TA, Copley TC (2001) Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 40:230-235
108. Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 6:32-44
109. Sahakian B, Morein-Zamir SC (2007) Cognitive enhancement: Professor's little helper. Nature 450:1157-1159
110. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL (2006) Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59:243-251
111. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N et al (2002) Doubleblind placebo-controlled trial of methylphenidate in the treatment of ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286-294
112. Shao C, Li Y, Jiang K, Zhang D, Xu Y, Lin L et al (2006) Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology 186:185-190
113. SolantoMV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attentiondeficit hyperactivity disorder: a review and integration. Behav Brain Res 94:127-152
114. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA et al (2006) PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am J Psychiatry 163:387-395
115. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005) Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology 182:186-193
116. Swanson JM, Volkow ND (2009) Psychopharmacology: concepts and opinions about the use of stimulant medications. J Child Psych Psychiatry 50:180-193
117. Szobot CM, Rohde LA, Bukstein O, Molina BSG, Martins C, Ruaro P et al (2007) Is attentiondeficit/ hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction 102:1122-1130
118. Szobot CM, Shih MC, Schaefer T, Júnior N, Hoexter MQ, Kai Fuet Y et al (2008a) Methylphenidate DAT binding in adolescents with attention-deficit/hyperactivity disorder comorbid with Substance Use Disorder-a single photon emission computed tomography with [Tc(99m)] TRODAT-1 study. NeuroImage 40:1195-1201
119. Szobot CM, Rohde LA, Katz B et al (2008b) A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 41:250-257
120. Szobot CM, Roman T, Hutz JP, Shih MC, Hoexter MQ, Junior N et al (2011) Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity. Synapse 65:154-159
121. Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK (2010) Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 49:573-582
122. Tiffany ST (1990) A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Res 97:147-168
123. Todd RD, Lobos EA, Sun LW, Neuman RJ (2003) Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry 8:103-108
124. Todd RD, Huang H, Smalley SL, Nelson SF, Willcutt BF, Pennington BF et al (2005) Collaborative analysis of DRD4 and DAT genotypes in population-defined ADHD subtypes. J Child Psychol 46:1067-1073
125. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004) Modafinil improves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biol Psychiatry 55:1031-1040
126. Volkow ND (2006) Stimulant medications: how to minimize their reinforcing effects? Am J Psychiatry 163:359-361
127. Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909-1918
128. Volkow ND, Swanson JM (2008) Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 165:553-555
129. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS et al (1995) Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52:456-463
130. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ (2002) Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 12:557-566
131. Volkow ND, Fowler JS, Wang G-J (2003) The addicted human brain: insights from imaging studies. J Clin Invest 111:1444-1451
132. Volkow ND, Fowler JS, Wang G-J (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1):3-13
133. Volkow ND, Wang G-J, Newcorn J, Telang F, Solanto MV, Fowler JS et al (2007) Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64:932-940
134. Volkow ND, Wang G-J, Kollins S, Wigal TM, Newcorn JH, Telang F et al (2009a) Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302:1084-1091
135. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009b) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301:1148-1154
136. White AM, Jordan JD, Schroeder KM, Acheson SK, Georgi BD, Sauls G et al (2004) Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. Subst Abus 25:53-59
137. WHO (2010) www.who.int/substnce_abuse/terminology/who_lexicon/en/index.html
138. Wilens TE (2007) The nature of the relationship between attention-deficit/hyperactivity disorder and substance use. J Clin Psychiatry 68(Suppl 1):4-8
139. Wilens TE, Biederman J, Millstein RB, Wozniak J, Hahesy AL, Spencer TJ (1999) Risk for substance use disorders in youths with child-and adolescent-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 38:680-685
140. Wilens TE, Monuteaux MC, Snyder LE, Moore H (2005) The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? J Child Adolesc Psychopharmacol 15:787-798
141. Wilens TE, Gignac M, Swezey A, Monuteaux M, Biederman J (2006) Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45:408-414
142. Wilens TE, Adler LA, Adams J et al (2008a) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31
143. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, Westerberg D et al (2008b) Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 162:916-921
144. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ et al (2008c) Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 96:145-154
145. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS et al (2010) Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Negat Results Biomed 71:1680-1688
146. Zack M, Belsito L, Scher R, Eissenberg T, CorrigallWA(2001) Effects of abstinence and smoking on information processing in adolescent smokers. Psychopharmacology (Berl) 153:249-257